Cargando…
Immune pressures drive the promoter hypermethylation of neoantigen genes
Cancer cells with strong immunogenicity are susceptible for elimination by cancer immunoediting, while the subpopulations with weak immunogenicity survive. As a result, a subset of cancer cells evade the immune attack and evolve into overt clinical lesions. During cancer evolution, it has been well...
Autores principales: | Yi, Ming, Dong, Bing, Chu, Qian, Wu, Kongming |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6884785/ https://www.ncbi.nlm.nih.gov/pubmed/31799063 http://dx.doi.org/10.1186/s40164-019-0156-7 |
Ejemplares similares
-
The role of neoantigen in immune checkpoint blockade therapy
por: Yi, Ming, et al.
Publicado: (2018) -
Bacteria pathogens drive host colonic epithelial cell promoter hypermethylation of tumor suppressor genes in colorectal cancer
por: Xia, Xiaoxuan, et al.
Publicado: (2020) -
SLIT2 promoter hypermethylation predicts disease progression in chronic myeloid leukemia
por: Wu, De-long, et al.
Publicado: (2022) -
Prognostic Values of TIM-3 Expression in Patients With Solid Tumors: A Meta-Analysis and Database Evaluation
por: Qin, Shuang, et al.
Publicado: (2020) -
Prognostic significance of KRT19 in Lung Squamous Cancer
por: Yuan, Xun, et al.
Publicado: (2021)